Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
05/09/2022 | 250.22% | SVB Leerink | $118 → $121 | Maintains | Outperform |
04/28/2022 | 79.45% | Credit Suisse | → $62 | Initiates Coverage On | → Neutral |
01/10/2022 | 250.22% | SVB Leerink | $116 → $121 | Maintains | Outperform |
01/05/2022 | 276.27% | Guggenheim | → $130 | Initiates Coverage On | → Buy |
11/09/2021 | 235.75% | SVB Leerink | $117 → $116 | Maintains | Outperform |
10/19/2021 | 238.64% | SVB Leerink | → $117 | Initiates Coverage On | → Outperform |
09/10/2021 | 334.15% | B of A Securities | → $150 | Initiates Coverage On | → Buy |
06/29/2021 | 331.26% | Wedbush | $114 → $149 | Maintains | Outperform |
05/11/2021 | — | Redburn Partners | Initiates Coverage On | → Buy | |
05/04/2021 | 146.02% | RBC Capital | → $85 | Initiates Coverage On | → Sector Perform |
03/01/2021 | 160.49% | Barclays | $47 → $90 | Downgrades | Overweight → Equal-Weight |
02/16/2021 | 319.68% | Wells Fargo | → $145 | Initiates Coverage On | → Overweight |
01/29/2021 | 189.44% | JP Morgan | $38 → $100 | Downgrades | Overweight → Neutral |
01/06/2021 | 143.13% | Stifel | → $84 | Initiates Coverage On | → Hold |
08/05/2020 | -4.49% | William Blair | → $33 | Initiates Coverage On | → Outperform |
03/02/2020 | -7.38% | Wedbush | → $32 | Initiates Coverage On | → Outperform |
03/02/2020 | -7.38% | Barclays | → $32 | Initiates Coverage On | → Overweight |
03/02/2020 | -7.38% | Jefferies | → $32 | Initiates Coverage On | → Buy |
Beam Therapeutics Questions & Answers
The latest price target for Beam Therapeutics (NASDAQ: BEAM) was reported by SVB Leerink on May 9, 2022. The analyst firm set a price target for $121.00 expecting BEAM to rise to within 12 months (a possible 250.22% upside). 9 analyst firms have reported ratings in the last year.
The latest analyst rating for Beam Therapeutics (NASDAQ: BEAM) was provided by SVB Leerink, and Beam Therapeutics maintained their outperform rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Beam Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Beam Therapeutics was filed on May 9, 2022 so you should expect the next rating to be made available sometime around May 9, 2023.
While ratings are subjective and will change, the latest Beam Therapeutics (BEAM) rating was a maintained with a price target of $118.00 to $121.00. The current price Beam Therapeutics (BEAM) is trading at is $34.55, which is out of the analyst's predicted range.